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CANCER
Aberrant expression of minichromosome maintenance
proteins 2 and 5, and Ki-67 in dysplastic squamous
oesophageal epithelium and Barrett’s mucosa
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Background: Minichromosome maintenance (Mcm) proteins are essential for eukaryotic DNA replica-
tion, and their expression implies potential for cell proliferation. Expression is dysregulated in dysplas-
tic states but data for oesophageal squamous mucosa and Barrett’s mucosa have not been published.
Aim: To test the hypothesis that Mcm proteins are downregulated together with the proliferation marker
Ki-67 in differentiating epithelial compartments of non-dysplastic squamous and Barrett’s epithelium,
and that this process does not occur in dysplastic mucosae.
Methods and cases: Forty five patients with Barrett’s oesophagus included 20 with glandular dyspla-
sia (10 low grade, eight high grade, two both, and four with invasive adenocarcinoma). Twenty five
other patients included 12 with oesophageal squamous dysplasia (three low grade, six high grade,
three both, and four with invasive squamous carcinoma). Formalin fixed paraffin embedded tissue sec-
tions from biopsy series and resections were immunostained using antibodies to Mcm2, Mcm5, and
Ki-67. Percentage of nuclei positive for Mcm2, Mcm5, and Ki-67 was estimated and scored from 0 to
6 as: 0, none +; 1, <10%+; 2, 10–30%+; 3, 30–70%+; 4, 70–90%+; 5, >90%+; 6, all+. Four sepa-
rate epithelial strata were scored: in squamous epithelium the basal layer and thirds to the surface, in
Barrett’s mucosa the luminal surface, upper and lower crypt, and deep glands.
Results: In non-dysplastic squamous epithelium and Barrett’s mucosa, high level expression of Mcm2,
Mcm5, and Ki-67 proteins was largely confined to the proliferative compartments and downregulated
in differentiated compartments. Expression persisted up to the mucosal surface in dysplastic squamous
epithelium and Barrett’s mucosa.
Conclusions: Persistent expression of Mcm2, Mcm5, and Ki-67 proteins in luminal compartments of
dysplastic oesophageal squamous epithelium and dysplastic Barrett’s mucosa may be diagnostic mark-
ers and imply disruption of cell cycle control and differentiation in these dysplastic epithelia.
L ethality of symptomatic oesophageal cancer motivatesscreening1–3 for earlier disease, treatable by surgicalresection or mucosal ablation by laser,4 argon beam,5 or
photodynamic therapy.6 Population screening for squamous
oesophageal carcinoma is only practised where the incidence
is high (for example, Japan and China). Dysplasia and
carcinoma surveillance by endoscopy and biopsy of Barrett’s
patients in Western populations is also undertaken, but with
uncertain benefit.7 It is a substantial commitment, rigorous
definition of Barrett’s dysplasia is difficult, and inter- and
intra-pathologist agreement is imperfect.8 9 Even four quad-
rant sampling with jumbo biopsy forceps does not guarantee
that all significant dysplasia will be detected,10 and the natural
history of oesophageal glandular dysplasia is obscure.
Abnormal proliferation and differentiation typify epithelial
dysplasia. Normal oesophageal squamous epithelial cells
divide slowly in the basal layer, proliferate suprabasally, and
mature towards the luminal surface.11 In Barrett’s mucosa,
despite its partially intestinal phenotype, proliferation and
differentiation patterns resemble gastric mucosa, with maxi-
mal proliferation in a crypt zone beneath the mucosal
surface12 and differentiation into deep glands and characteris-
tic cell populations on the mucosal surface (in normal small
intestine, stem cells in the crypts of Lieberkühn feed a prolif-
erative compartment from which differentiating enterocytes
and goblet cells migrate to the villi11 while Paneth cells migrate
basally).
Proliferation and differentiation compartments break down
in dysplastic epithelia. “Dysplastic” cells adjacent to an
invasive carcinoma probably represent the neoplastic clone
from which the carcinoma emerged. Dysplasia alone implies
an increased cancer risk, and motivates eradication or
increased intensity of surveillance. Difficulty in reliably recog-
nising and grading dysplasia is therefore therapeutically
relevant, and improved methods for doing so are desirable.
In eukaryotic cells, initiation of DNA synthesis at specific
sites (origin firing) is tightly restricted to permit duplication
of the genome once only per cell cycle.13 Initiation factors
including the origin recognition complex, Cdc6,14 and mini-
chromosome maintenance (Mcm) proteins which assemble
during G1 into pre-replicative complexes (pre-RCs) at replica-
tion origins to establish competence for DNA replication in S
phase. Activated Cdc7/Dbf4 kinase14 and S phase promoting
cyclin dependent kinases trigger unwinding of replication ori-
gins and establish bidirectional replication forks, and disas-
sembly of pre-RCs during replication prevents reinitiation of
DNA replication within a single cycle.
When mammalian cells exit the cell cycle into quiescent,
differentiated, and senescent states, the Cdc6 and Mcm com-
ponents of the pre-RCs are downregulated,15 16 and dysregu-
lated expression of these proteins is characteristic of both dys-
plastic cervical squamous epithelium16 and urothelium.17 It
seemed appropriate therefore to evaluate their potential as
markers of dysplasia and dysregulated cell cycle control in
normal oesophageal squamous epithelium, Barrett’s mucosa
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without dysplasia, and in their dysplastic and neoplastic
counterparts.
MATERIALS AND METHODS
Production of antibodies
Anti-Mcm2 monoclonal antibody (mAb) (mouse IgG1 iso-
type) was raised against a fragment of human Mcm2 (amino
acids 725–888; BM28, Transduction Laboratories, Lexington,
Kentucky, USA). The specificity of the anti-Mcm2 mAb was
established by immunoblot, immunofluorescence, and immu-
noprecipitation assays. Rabbit polyclonal antibodies were
raised against a fragment of human Mcm5 (amino acids 372–
590) and purified by affinity chromatography over a column
prepared by linking the immunogen to Sulfolink Gel (Pierce,
Rockford, Illinois, USA). Specificity of anti-Mcm2 mAb and
anti-Mcm5 polyclonal antibody was established by immunob-
lot, immunofluorescence, and immunoprecipitation assays.
The anti-Ki-67 mAb MIB1 was supplied by Dako (Ely,
Cambridge, UK).
Immunohistochemistry
Preliminary testing of six different antibodies at different
dilutions and antigen retrieval schedules including enzymatic
digestion and microwave heating in citrate and EDTA buffer
was performed on formalin fixed paraffin embedded tissue
sections. Good results were obtained with antibodies against
Mcm proteins 2 and 5 using EDTA buffer and microwave
heating antigen retrieval. Both Mcm antibodies were used
diluted 1:4000 and conventional three stage streptavidin/
biotin and peroxidase with diaminobenzidine/H202 detection.
Antibody MIB1 was applied diluted 1:100 following micro-
wave antigen retrieval and detected as for Mcm2/Mcm5.
Cases
Seventy patients were studied. Twenty five patients without
Barrett’s oesophagus included 13 with no squamous dyspla-
sia, three with low grade squamous dysplasia, six with high
grade squamous dysplasia, and three with both. Four patients
in this group also had invasive squamous carcinoma. Forty five
patients with Barrett’s oesophagus included 25 without
dysplasia, 10 with low grade glandular dysplasia, eight with
high grade dysplasia, and two with both. Four patients in this
group also had invasive adenocarcinoma.
Patients were from cohorts undergoing diagnostic endos-
copy for upper gastrointestinal symptoms, enrolled in a yearly
surveillance of Barrett’s oesophagus, or having surgical resec-
tion of oesophageal carcinoma. Dysplastic changes were
Figure 1 Graphs of minichromosome maintenance protein (Mcm)
and Ki-67 expression in oesophageal squamous epithelium: quartile
plots of immunohistochemical scores (range 0–6) for Ki-67, Mcm5,
and Mcm2 (rows 1–3). Columns from left to right represent
squamous epithelium without dysplasia (none), low grade dysplasia
(LGD), and high grade dysplasia (HGD). Epithelial layers are
represented as a–d with a=basal; b=suprabasal, lower third;
c=suprabasal, middle third; and d=suprabasal, upper third. Filled
dots represent medians, bars interquartile range, and small open
dots the range.
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Figure 2 Graphs of minichromosome maintenance protein (Mcm)
and Ki-67 expression in Barrett’s mucosa: quartile plots of
immunohistochemical scores (range 0–6) for Ki-67, Mcm5, and
Mcm2 (rows 1–3). Columns from left to right represent Barrett’s
mucosa without dysplasia (none), low grade dysplasia (LGD), and
high grade dysplasia (HGD). Mucosal layers are represented as a–d
with a=deep glands; b=lower crypt; c=upper crypt; and d=mucosal
surface. Filled dots represent medians, bars interquartile range, and
small open dots the range.
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assessed on haematoxylin and eosin stained sections of paraf-
fin embedded endoscopic biopsies and tissue blocks from
resection specimens which were chosen from pathology
department archives to represent a range of morphologies
from normal (non-dysplastic) oesophageal squamous epithe-
lium through low and high grade squamous dysplasia to inva-
sive squamous carcinoma. Similarly, examples of Barrett’s
mucosa without dysplasia, low grade and high grade dysplasia
in Barrett’s mucosa, and invasive Barrett’s adenocarcinoma
were selected for study, and 4 µm sections were immuno-
stained as described.
Scoring immunocytochemistry
A semiquantitative scoring scheme was designed to describe
the immunostaining observed. Cell nuclei were positive or
negative for Mcm2, Mcm5, or Ki-67. All scoring was done by
one specialist upper gastrointestinal pathologist (JJG). Within
each separate mucosal compartment, the estimated percent-
age of positive cells was allocated to scoring bands as follows:
0, none+; 1, <10%+; 2, 10–30%+; 3, 30–70%+; 4, 70–90%+;
5, >90%+; and 6, all+. Four compartments were recognised in
oesophageal squamous epithelium: the most basal single layer
of cells, and the thickness of the epithelium above that divided
into parabasal, middle, and luminal thirds. In Barrett’s
mucosa, four strata again were defined: the surface epithelium
between “crypts”, the underlying “crypts” or “pits” divided
into upper and lower halves, and the deepest layer, a differen-
tiated glandular zone. These compartments correspond to
those defined by Lauwers and colleagues18 in their study of cell
proliferation in Barrett’s mucosa.
Reproducibility of scoring and statistical analysis
Reproducibility of scoring was evaluated by “blind” re-scoring
by JJG of all sections stained for Mcm2 after six months.
Weighted kappa κw
19 was calculated for duplicate scores from
562 separate cellular populations; κw=0.65 implied acceptable
agreement. Univariate statistical significance of differences
between immunostaining was tested using the non-
parametric Mann-Whitney test for two independent samples,
two tailed, with correction for ties. Kappa and Mann-Whitney
calculations were performed in Analyse-It for Microsoft Excel
(Analyse-It Software, Leeds, UK).
RESULTS
Immunostaining with the Mcm2 antibody yielded predomi-
nantly nuclear staining. The Mcm5 antibody stained nuclei
but also cell membranes in glandular mucosae and tumours.
Qualitatively, nuclear staining was similar with the two
antibodies. Ki-67 staining was purely nuclear.
In non-dysplastic squamous epithelium and Barrett’s
mucosa, strong Mcm2, Mcm5, and Ki-67 staining of most to
Figure 3 Minichromosome maintenance protein 2 (Mcm2)
expression in Barrett’s mucosa. On the right of (A), non-dysplastic
intestinal type “specialised” Barrett’s mucosa shows Mcm2
expression in cells of the proliferative zone beneath the mucosal
surface. Expression falls away markedly on the mucosal surface.
There is an abrupt transition (arrow) to mucosa showing mild (low
grade) dysplasia in which Mcm2 downregulation does not occur.
More pronounced but still low grade Barrett’s dysplasia (B) shows
strong Mcm2 expression in the upper crypt and surface, with weaker
expression in deep glands.
Figure 4 Minichromosome maintenance protein 2 (Mcm2)
expression in oesophageal squamous epithelium. In normal
squamous epithelium (A), maximal expression immediately above a
well defined basal layer falls to undetectable levels in the upper third
(top). In low grade dysplasia (B), detectable Mcm2 persists to the
luminal surface. In (C), there is an abrupt transition between high
grade squamous dysplasia (right) and morphologically normal
oesophageal squamous epithelium (left). The apparent “island” of
Mcm2 expression (small arrow) in the normal epithelium represents
tangential sectioning of a submucosal papilla.
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all nuclei was present in the expected proliferative transit
compartment—that is, the suprabasal compartment of
squamous epithelium—and in the lower crypt compartment
of Barrett’s mucosa. In differentiated compartments—that is,
the surface of squamous epithelium and Barrett’s mucosa—
and in the small differentiated deep glands of Barrett’s
mucosa, expression was downregulated. In dysplastic
squamous epithelium and dysplastic Barrett’s mucosa there
was persistence of Mcm2, Mcm5, and Ki-67 expression in
compartments in which they are normally absent or sparse,
especially towards the surface of squamous epithelium and
Barrett’s mucosa. Downregulation of Mcm2 and Mcm5
expression in the deep (glandular) mucosal compartment of
Barrett’s mucosa was also significantly reduced in high grade
dysplasia. These relationships are illustrated in figs 1 and 2
which plot median, quartiles, and range for Mcm2, Mcm5, and
Ki-67 staining scores for the various compartments of
oesophageal squamous (fig 1) and Barrett’s mucosa (fig 2).
Photomicrographs illustrate these staining patterns (fig 3A–C
for Barrett’s mucosa and fig 4A, B for squamous epithelium).
Statistical testing confirms that overexpression of these
markers in the surface and subsurface compartments of dys-
plastic squamous and Barrett’s mucosa is significant at a high
level of probability (table 1).
Although abnormally persistent expression of Mcm2,
Mcm5, and Ki-67 is clearly associated with premalignant dys-
plasia in oesophageal squamous epithelium and Barrett’s
mucosa, variant patterns were identified. The dysplastic
squamous epithelium in fig 5A clearly downregulates Mcm2
expression towards the surface, and in the same case Mcm2
downregulation occurs in invasive squamous carcinoma
towards the centre of cell nests—that is, in areas of differen-
tiation (fig 5B). Similarly, viable but Mcm2 and Mcm5
negative cells were present in invasive adenocarcinomas (fig
6).
DISCUSSION
Our data document spatial organisation of cell proliferation in
normal oesophageal squamous epithelium and non-dysplastic
Barrett’s mucosa, and disruption of this highly organised spa-
tial arrangement in premalignant dysplasia. These distur-
bances are relevant to the identification of dysplasia in
oesophageal squamous epithelium and Barrett’s mucosa, both
of which are problematic in individuals and populations.
Squamous oesophageal cancer is a target for screening in Far
Eastern populations. Barrett’s oesophagus and Barrett’s
cancer are relatively common in the West. Patients with
Barrett’s oesophagus may be subjected to relatively frequent
endoscopy and biopsy (for example, yearly). A sensitive and
specific test for dysplasia might allow Barrett’s patients to be
screened for dysplasia and divided into a cohort without dys-
plasia, at low risk of oesophageal adenocarcinoma, for whom
less intensive follow up would be safe, and a higher risk group,
with dysplasia, for whom more frequent endoscopic and
biopsy surveillance could be appropriate. A sensitive test for
early dysplastic changes in endoscopic biopsies would be use-
ful to the pathologist although to date various tests that have
been proposed have been disappointing in practice.
Abnormal expression of Mcm5 protein in dyskaryotic
cervical smears is associated with cervical intraepithelial neo-
plasia, and immunocytochemistry for Mcm5 protein facili-
tates detection of dyskaryotic cells in such smears, which may
otherwise be a problem if they are present in small
numbers.16 Similarly, biochemical assay of these proteins in
urine is a sensitive and specific test for the presence of urothe-
lial epithelial neoplasia.17 These examples and the present
Table 1 p values by Mann-Whitney testing of the
differences between groups
Ki67 Mcm5 Mcm2
Squamous mucosa
Surface
Normal v LGD <0.0001 0.0005 0.0029
Normal v HGD <0.0001 <0.0001 <0.0001
Subsurface
Normal v LGD <0.0001 0.0016 0.0022
Normal v HGD <0.0001 <0.0002 <0.0001
Parabasal
Normal v LGD NS NS NS
Normal v HGD NS NS 0.0216
Basal
Normal v LGD 0.0039 0.0498 NS
Normal v HGD 0.0113 0.0118 0.0048
Barrett’s mucosa
Surface
Normal v LGD <0.0001 <0.0001 <0.0001
Normal v HGD <0.0001 <0.0001 <0.0001
Upper crypt
Normal v LGD <0.0001 0.0002 0.0002
Normal v HGD 0.0009 0.0027 <0.0001
Lower crypt
Normal v LGD NS NS NS
Normal v HGD NS NS NS
Deep glands
Normal v LGD NS 0.0117 NS
Normal v HGD 0.0055 NS 0.0059
LGD, low grade dysplasia; HGD, high grade dysplasia.
Figure 5 Downregulation of minichromosome maintenance protein
2 (Mcm2) with differentiation in dysplastic and neoplastic squamous
epithelium. In (A), full thickness squamous dysplasia with Mcm2
expression up to the mucosal surface (on the left of the picture) is
associated with a basaloid phenotype. On the right, marked nuclear
atypia persists to the mucosal surface but cells towards the surface
have more cytoplasm and this morphological change is associated
with loss of detectable Mcm2. Similarly, in a moderately
differentiated invasive oesophageal squamous carcinoma (B), many
carcinoma cells are Mcm2 positive but viable Mcm2 negative
carcinoma cells are present within cell nests with morphological
features of differentiation (keratinisation).
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study support the use of Mcm proteins (and Ki-67) as mark-
ers of dysplasia. These studies in cervix, bladder, and oesoph-
agus support the concept that persistence of Mcm protein
expression in dysplastic epithelia is associated with preneo-
plastic cells locked in the cell cycle (confirmed by persistence
of Ki-67 expression) compared with normal epithelial cells
that exit the cell division cycle during maturation and differ-
entiation.
A problem in Barrett’s surveillance is that dysplastic
changes may be very focal, and biopsy series may not sample
dysplasia, even if large biopsy forceps are used
systematically.10 Aberrant superficial expression of Mcm2,
Mcm5, and Ki-67 proteins by dysplastic Barrett’s mucosa
suggests that exfoliative cytology could be used to sample
more widely than biopsy procedures. Brush cytology could be
directed at endoscopy or a balloon cytology catheter employed
to collect cells from the mucosal surface.3 20 Balloon cytology
does not require endoscopy. Sampled cells could be evaluated
by immunohistochemistry or biochemically. The data pre-
sented here justify critical prospective evaluation in an appro-
priate clinical setting of Mcm proteins as candidate markers of
dysplasia and cancer risk in squamous and columnar lined
oesophagus.
Although persistence of Mcm2 and 5 proteins in differenti-
ating compartments of dysplastic squamous oesophageal epi-
thelium and Barrett’s mucosa is characteristic, it is not invari-
able. Downregulation can occur in surface cells overlying
clearly atypical cells of squamous and glandular mucosae.
These surface cells may themselves appear atypical, or
relatively normal in morphology. One interpretation of this
appearance is the biologically trivial one that the morphologi-
cally normal cells may appear to be related to the underlying
cells only as a consequence of vagaries of the plane of section
in randomly orientated mucosal biopsies. Histological
interpretation of Barrett’s dysplasia routinely requires this to
be taken into account. However, our own data show that even
in invasive carcinomas, molecular events associated with
differentiation appear capable of switching off Mcm protein
expression. These findings support the concept of mutual
antagonism between the cellular circuits controlling differen-
tiation and proliferation. As this would usually be understood
to prevent further cell division, such events may have
therapeutic relevance.
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Figure 6 Minichromosome maintenance protein 2 (Mcm2)
expression in an oesophageal adenocarcinoma. This carcinoma was
in a Barrett’s oesophagus. Malignant glandular acini invade
muscularis propria. Most of the carcinoma cells are Mcm2 positive
but viable Mcm2 negative carcinoma cells are also present.
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